Mark Eccleston
Direttore Tecnico/Scientifico/R&S presso VOLITIONRX LIMITED
Profilo
Mark Eccleston was the founder of Vivamer Ltd.
(founded in 2002) and held the title of Chief Scientific Officer from 2002 to 2006.
He is currently the Director of Business Development at Volition, Inc., the Managing Director at Oncolytika Ltd.
(since 2010), and the Chief Technology Officer at VolitionRX Ltd.
Dr. Eccleston's former job was as the Director of ADD Signs Ltd.
(2010-2017).
He obtained an MBA from the University of Dundee in 2008 and a doctorate from the University of Aston in 1998.
Posizioni attive di Mark Eccleston
| Società | Posizione | Inizio |
|---|---|---|
| VOLITIONRX LIMITED | Direttore Tecnico/Scientifico/R&S | 01/02/2021 |
Volition, Inc.
 Volition, Inc. Packaged SoftwareTechnology Services Volition, Inc. operates as a video game developer firm. The company was founded on March 14, 1997 and is headquartered in Champaign, IL. | Corporate Officer/Principal | - |
Oncolytika Ltd.
 Oncolytika Ltd. Miscellaneous Commercial ServicesCommercial Services Oncolytika Ltd. is a British technical consultancy company that provides research and development services in biotechnology. The private company is based in Cambridgeshire, UK. Mark Eccleston has been the CEO of the company since 2010. | Amministratore Delegato | 01/06/2010 |
Precedenti posizioni note di Mark Eccleston
| Società | Posizione | Fine |
|---|---|---|
ADD Signs Ltd.
 ADD Signs Ltd. Miscellaneous ManufacturingProducer Manufacturing ADD Signs Ltd. provides a professional service designing and manufacturing architectural and retail sign systems. Its services include signs, graphics, development and property, and vehicles. The company is headquartered in Liverpool, the United Kingdom. | Direttore/Membro del Consiglio | 03/02/2017 |
Vivamer Ltd.
 Vivamer Ltd. BiotechnologyHealth Technology Vivamer Ltd. manufactures drugs based on biopolymer chemistry. The firm’s polymer chemistry platform provides a unique and novel drug delivery system. It protects traditional molecule and biotech drugs from degradation in the body. The company was founded by Nigel Slater and Mark Eccleston on December 3, 2002 and is headquartered in Cambridge, the United Kingdom. | Amministratore Delegato | - |
Formazione di Mark Eccleston
| University of Aston | Doctorate Degree |
| University Of Dundee | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VOLITIONRX LIMITED | Health Technology |
| Aziende private | 4 |
|---|---|
Vivamer Ltd.
Vivamer Ltd. BiotechnologyHealth Technology Vivamer Ltd. manufactures drugs based on biopolymer chemistry. The firm’s polymer chemistry platform provides a unique and novel drug delivery system. It protects traditional molecule and biotech drugs from degradation in the body. The company was founded by Nigel Slater and Mark Eccleston on December 3, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
ADD Signs Ltd.
ADD Signs Ltd. Miscellaneous ManufacturingProducer Manufacturing ADD Signs Ltd. provides a professional service designing and manufacturing architectural and retail sign systems. Its services include signs, graphics, development and property, and vehicles. The company is headquartered in Liverpool, the United Kingdom. | Producer Manufacturing |
Volition, Inc.
Volition, Inc. Packaged SoftwareTechnology Services Volition, Inc. operates as a video game developer firm. The company was founded on March 14, 1997 and is headquartered in Champaign, IL. | Technology Services |
Oncolytika Ltd.
Oncolytika Ltd. Miscellaneous Commercial ServicesCommercial Services Oncolytika Ltd. is a British technical consultancy company that provides research and development services in biotechnology. The private company is based in Cambridgeshire, UK. Mark Eccleston has been the CEO of the company since 2010. | Commercial Services |
- Borsa valori
- Insiders
- Mark Eccleston
